Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
Business Wire•04/11/2026•16:36 ET
0
Key Highlights
- ➤AstraZeneca completed a $2.0 billion strategic equity investment in Summit on October 5, 2026
- ➤Summit ended Q3 with $629.8 million in cash and investments
- ➤HARMONi-2 showed ivonescimab improved overall survival versus pembrolizumab, HR 0.73
- ➤HARMONi-GI1 showed ivonescimab improved overall survival versus durvalumab plus chemotherapy, HR 0.75
- ➤HARMONi-3 squamous-cohort PFS events are expected in Q4 2026, with an early OS analysis planned
Expert Statements
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics
“This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others”
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics
“These commitments underscore ever growing confidence in ivonescimab’s potential across a broad range of solid tumors.”
Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
“Our global clinical development program for ivonescimab continues to broaden, with the announcement of ivonescimab combination collaborations with Datroway® and sone-ve, alongside new studies in bladder cancer with HARMONi-GU1, in biliary tract cancer with EA2251, and in kidney cancer with SMT112-216 and Arcus’ ARC-20 platform study.”
Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
“We are encouraged by the statistically significant overall survival results recently presented from Akeso’s HARMONi-2 study in PD-L1–positive advanced NSCLC and HARMONi-GI1 study in BTC, and we look forward to the upcoming initial HARMONi-3 data in first-line squamous NSCLC.”
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and Summit’s Expanding Network of Clinical Collaborations Underscore Confidence in Ivonescimab’s Potential
Get started
Create a free account to read the full story.